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expression of menin, the product of the MEN1 (multiple endocrine neoplasia type 1) tumor suppres-
sor gene, represents a common feature of several fatty liver mouse models. The liver speciﬁc abla-
tion of MEN1 gene expression in healthy mice induced hepatic steatosis under high-fat dietary
conditions. Moreover, overexpression of menin in livers of steatotic db/db mice reduced liver tri-
glyceride accumulation. At the molecular level, we found that menin acts synergistically with the
nuclear receptor PPARa to control gene expression of fatty acid oxidation. Collectively, these data
suggest a crucial role for menin as an integrator of the complex transcriptional network controlling
hepatic steatosis.
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Menin physically interacts with PPAR alpha by anti tag coimmunoprecipitation (View Interaction: 1, 2).
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Non-alcoholic fatty liver disease (NAFLD) has emerged as an
important public health problem because of its high prevalence,
potential progression to severe liver disease and association with
serious metabolic syndrome, including type 2 diabetes mellitus,
atherosclerosis and coronary heart disease [1,2]. Although it has
been connected with numerous impairments of energy homeosta-
sis, the molecular determinants of fatty liver development remain
largely unexplored.
There is an intense interest in the roles of transcription factors in
the pathogenesis of NAFLD, particularly the peroxisome proliferator
activated receptor alpha (PPARalpha). When activation, PPARalpha
formes a heterodimer with the nuclear receptor RXR and binds to
speciﬁc DNA-response elements in the promoter of target genes
[3]. The genomic sequence recognized by PPARalpha consists of a
direct repeat of the consensus hexameric motif AGGTCA inter-
spaced by a single nucleotide [4]. PPARalpha is highly expressed
in liver where it stimulates fatty acid uptake and activation, mito-
chondrial b-oxidation, peroxisomal fatty acid oxidation, ketogene-
sis and fatty acid elongation and desaturation [5–7]. In addition,
transcriptional cofactor complexes have been identiﬁed as critical
checkpoints in the coordination of metabolic programs throughchemical Societies. Published by Eactivation or repression of PPARalpha, exempliﬁed by peroxisome
proliferator-activated receptor coactivator 1 (PGC-1alpha), SIRT1,
or the steroid hormone receptor coactivators [8–10]. In this respect,
we hypothesized that the dysregulated gene expression of distinct
transcriptional cofactor of PPARalpha under fatty liver conditions
directly mirrors alterations of hepatic lipid homeostasis and may
causally contribute to the fatty liver phenotype.
In this study, we identify the inhibition of menin gene expres-
sion as a conserved and functionally important checkpoint in the
manifestation of liver steatosis. Menin, encoded by the MEN1 gene,
was identiﬁed as the pathogenic gene for beta cell tumor formation
in patients with multiple endocrine neoplasia type 1 [11,12]. Sub-
sequently, it has been considered as a negative regulator in pancre-
atic beta cell proliferation [13,14]. Menin has been shown to be a
histone methyltransferase protein complex containing MLL, which
promotes trimethylation of histone H3 on lysine 4, a epigenetic
mark associated with transcriptionally active chromation [15,16].
However, the biological and in particular, liver speciﬁc functions
of menin remained largely unknown.
2. Materials and methods
2.1. Animal experiments
Male 10- to 12-week-old C57BL/6 and db/db mice were
obtained from Shanghai Laboratory Animal Company (SLAC,lsevier B.V. All rights reserved.
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with access to water and diet. Normal diet and high fat diet were
purchased from SLAC, which contained 10% kcal and 60% kcal cal-
ories, respectively. For adenovirus injections, 2  109 plaque-form-
ing units (pfu) per recombinant virus were administrated via tail
vein injection. Mice (including mice treated with viruses or high
fat diet food) were sacriﬁced for further analysis after fasting for
10 h. For intralipid infusions, mice were fasted for 12 h, and
200 ll of a 20% (v/v) intra-lipid emulsion in saline was adminis-
trated intravenously. Mice were sacriﬁced and liver tissues were
collected 12 h after infusion.
2.2. Lipids and glucose analysis
Trunk blood was harvested in EDTA tubes on ice and plasma
was stored at 70 C. Lipids were extracted from liver in chloro-
form/methanol (2:1, v/v) and washed in 50 mM NaCl. Samples
were redissolved in 50 ml of 1:1 chloroform/Triton X-100. All sam-
ples were measured using commercial kits (Thermo, USA), accord-
ing to the manufacturer’s instructions. Blood glucose levels were
determined using an automatic glucosemonitor (One Touch,
Lifescan).
2.3. RNA extraction and real-time PCR analysis
Total RNAs were extracted from tissues or cells using TRIzol
reagent (Invitrogen, USA) according to the manufacturer’s protocol.
Five hundred nanograms of total RNA was used for cDNA synthesis
using oligo (dT) primers (Promega, USA). Real-time PCR was per-
formed using a SYBR Green Premix Ex Taq (Takara, Japan) in an
Applied Biosystems 7900 Machine. Following an initial denatur-
ation at 95 C for 30 s, 40 cycles of PCR ampliﬁcation were per-
formed at 95 C for 5 s and 60 C for 30 s. Standard curves were
generated and the relative amount of target gene mRNA was nor-
malized to GAPDH. The speciﬁcity was veriﬁed by melt curve anal-
ysis and agarose gel electrophoresis. The sequences of all used
primers are listed below:
Mouse menin
Forward: 50-CGATCTTCACACTGACTCTTTGG-30,
Reverse: 50-AGGTCTGCCAAGTTCCCTAGC-30;
Mouse CPT1beta
Forward: 50-AGGCACTTCTCAGCATGGTC-30,
Reverse: 50-GCTTCAGGGTTTGTCGGAAGA-3;
mouse MCAD
Forward: 50-AGTACCCGTTCCCTCTCATCA-30,
Reverse: 50-TACACCCATACGCCAACTCTT-30;
Mouse Acox1
Forward: 50-GATTCTGAACGATCCAGACTTCC-30,
Reverse: 50-CACCTCGTAACGCTGGCTT-30;
Mouse GAPDH
Forward: 50-GTATGACTCCACTCACGGCAA-30,
Reverse: 50-CTTCCCATTCTCGGCCTTG-30.
2.4. Cell culture and luciferase assay
HeLa and HepG2 cells were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM)/F12 (1:1) medium (Invitrogen, USA). Ade-
noviruses expressing menin-speciﬁc shRNA were obtained from
Santa Cruz Company (sc-35923) and constructed under control of
the U6 promoter. Viruses were puriﬁed by the cesium chloride
method and dialyzed against phosphate-buffered-saline buffer.
Primary mouse hepatocytes were transiently transfected with me-
nin-speciﬁc or non-speciﬁc shRNA for 36 h before harvest. For
luciferase assays, cells were seeded into 24-well plates and trans-
fected with the indicated plasmids using Lipofectamine 2000(Invitrogen) according to the manufacturer’s instructions. Two
hundred nanograms of GalTK-luciferase construct and 200 ng of
the expression plasmid for Gal4-PPARalpha (AF2) were co-trans-
fected into HepG2 cells. Luciferase activity was measured using
the Dual Luciferase Reporter Assay System (Promega, USA) and
repeated for ﬁve times.
2.5. Immunoprecipitation
HeLa cells were transfected with HA-Menin or His-PPARalpha
for 48 h. Cells were harvested and lysed in lysis buffer (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 0.5% Nonidet P40, Roche complete
EDTA-free protease inhibitor cocktail). Lysates were cleared by
centrifugation and supernatants were subjected to immunoprecip-
itation (IP) with immobilized anti-HA (Sigma) resin overnight.
After extensive washing, 2 SDS loading buffer was added into
the resin and boiled. The samples were loaded and separated by
SDS–PAGE and immunoblotted with a His-Tag antibody.
2.6. Statistics
Values were reported as mean ± SEM. Statistics analyses were
performed using a Student’s t test. Statistical signiﬁcance is dis-
played as ⁄(P < 0.05), ⁄⁄(P < 0.01) or ⁄⁄⁄(P < 0.001).3.Results
3.1. Hepatic menin expression is down-regulated in fatty liver mouse
models
If menin is involved in the regulation of lipid homeostasis, it
would be anticipated that its expression is altered in mice models
of fatty liver. We ﬁrst examined a mouse model of severe genetic
obesity resulting from leptin receptor deﬁciency (also known as
db/db mice). Quantitative real-time reverse-transcription poly-
merase chain reaction (Real-time PCR) and western immunoblot-
ting analyses showed a dramatic decrease in the messenger RNA
(mRNA) and protein expression levels of menin in the livers of
db/db mice, in comparison with wild-type littermates (Fig. 1A
and B). In contrast, comparable menin expression levels were
detected in the white adipose tissue (data not shown). To test
whether the hepatic inhibition of menin represents a more
common feature of obesity-related dyslipidemia, we studied
high-fat-diet-fed (HFD) mice as an independent standard model
for nutrition-induced obesity. Indeed, menin mRNA and protein
levels were found to be reduced in livers of HFD mice as compared
with controls (Fig. 1C and D).
To identify potential triggers of Menin gene inhibition under
these conditions, we next used an in vivo lipid infusion system,
which acutely increases circulating free fatty acids (FFA) and
causes insulin resistance. In this setting, there was also a dramatic
decrease in menin expression in mice following lipid exposure
(Fig. 1E). Moreover, exposure of HepG2 cells to palmitate signiﬁ-
cantly inhibited menin mRNA levels (Fig. 1F), further suggesting
that fatty acids can impair menin expression in obesity related
conditions.
3.2. Liver speciﬁc menin deﬁciency promotes hepatic steatosis
To address the liver-speciﬁc function of menin, we disrupted its
expression in livers of lean C57BL/6 mice by delivering an adenovi-
rus expressing menin-speciﬁc or non-speciﬁc control shRNA via
tail vein injection. Menin shRNA treatment signiﬁcantly reduced
hepatic menin mRNA and protein levels as compared with control
shRNA-injected littermates (Fig. 2A and B). Acute knockdown of
Fig. 2. Inhibition of hepatic menin results in liver steatosis. (A and B) mRNA (A) and protein (B) levels of hepatic menin from mice injected with menin-shRNA or control-
shRNA viruses, n = 8. (C–H) Serum cholesterol (C), blood glucose (D), liver triglyceride (E), liver weight (F), serum triglyceride (G) and serum fatty acid (H) levels in the same
mice as in (A), n = 8.
Fig. 1. Hepatic expressionofmenin is reduced in fatty livers. (AandB):mRNA(A) andprotein (B) analysis of liver extracts fromwild-type leanmiceordb/dbmice,n = 6. (C andD):
MeninmRNA (C) andprotein (D) levels in livers ofmice fed anormal diet (ND)or high fat diet (HFD),n = 7. (E)MeninmRNA levels in livers of C57BL/6mice injectedwith intralipid
emulsion for 12 h, n = 5. (F) Menin mRNA levels in HepG2 cells treated with 0.5 mM palmitate or 0.5% BSA for 24 h. Bars correspond to mean ± SEM from four experiments.
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Fig. 3. Restoration of hepatic menin expression improved fatty livers in db/db Mice. (A) Menin expression in livers of db/db mice following adenoviral expression of menin
(Ad-Menin) or control vector (Ad-GFP), n = 6. (B–F) Liver triglyceride contents (B), serum triglyceride (C), serum fatty acid (D), serum cholesterol (E) and blood glucose levels
(F) were determined in mice as indicated in (A), n = 6. (G) Representative hematoxylin and eosin staining of liver sections from mice as indicated in (A). (H) Liver weight from
two groups of mice were determined.
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blood glucose levels (Fig. 2C and D), body weight, food intake
and total body fat content (data not shown). In contrast, loss of
hepatic menin resulted in a signiﬁcant increase in triglyceride con-
tent and liver weight (Fig. 2E and F), indicating that menin pre-
dominantly prevents hepatic TG accumulation in wild-type
animals. Moreover, abrogation of hepatic menin resulted in an
increase in serum triglyceride and fatty acid levels (Fig. 2G and H).
3.3. Restoration of hepatic menin in db/db mice prevents liver steatosis
Because menin is dramatically down-regulated in livers of
db/db mice, we reasoned that reconstitution of menin expression
might be an effective way to prevent the progression of liver stea-
tosis. Therefore, we expressed menin using an adenoviral system in
the liver tissue of db/db animals to examine its metabolic impact.
After adenoviral delivery, we veriﬁed that expression of menin
was signiﬁcantly elevated (4-fold) in the liver tissue of obese
mice, compared to vector controls (Fig. 3A). Indeed, this increase
in the expression of menin in db/db mice led to decreased hepatic
TG content (Fig. 3B) and serum TG, FFA levels (Fig. 3C and D), while
serum cholesterol, and blood glucose levels remained unaffected
(Fig. 3E and F). Results from histological examination on hepatic
sections also conﬁrmed our observations (Fig. 3G), showing an
improved triglyceride accumulation in mice over-expressedmenin.
Besides, menin overexpression markedly alleviated the hepato-
megaly, as shown by a signiﬁcant decrease in the liver weight
(Fig. 3H).3.4. Menin cooperates with nuclear receptor PPARalpha to improve
liver steatosis
To determine whether changes in the fatty acid oxidation path-
way contribute to the observed phenotype in menin-depleted ani-
mals, we measured the circulating levels of total ketone bodies and
found that mice deﬁcient in hepatic menin showed decreased lev-
els of ketone bodies in the serum (Fig. 4A), indicating reduced
hepatic oxidation of fatty acids. Consistently, real-time PCR analy-
sis revealed particularly decreased expression of genes in the mito-
chondrial and peroxisomal fatty acid oxidation pathways (Fig. 4B),
suggesting that disruption of menin expression promotes liver
steatosis by speciﬁcally blunting fatty acid combustion.
The nuclear receptor PPARalpha has been identiﬁed as a master
regulator of fatty acid oxidation in the liver, prompting us to test
whether menin might serve as a physiological coactivator for
PPARalpha. Indeed, we found a ligand independent interaction
between menin and PPARalpha (Fig. 4C and D). To further study
the mechanism of co-activation of PPARalpha by menin, we per-
formed luciferase reporter assays. To this end, HepG2 cells were
transiently transfected with increasing amounts of menin together
with the expression vector for a fusion protein containing the AF2
domain of PPARalpha fused to the DNA binding domain of the
yeast Gal4 activator. We found that menin could enhance this
luciferase reporter in a dose dependent manner (Fig. 4E). More-
over, inhibition of menin expression in primary mouse hepatocytes
reduced the induction of prototypic PPARalpha target genes
(Fig. 4F and G), demonstrating that menin is indeed required for
Fig. 4. Menin cooperates with nuclear receptor PPARalpha. (A) Total serum ketone body levels were determined in mice injected with menin or control shRNA viruses, n = 8.
(B) mRNA levels of fatty acid oxidation in livers of the same mice as in (A), n = 8. (C and D) Co-immunoprecipitation assays performed with HA-menin and His-PPARalpha in
HeLa cells. (E) Menin promoted PPARalpha transcriptional activity in a dose dependent manner in a luciferase reporter assay. (F) Western blot analysis of menin expression
levels in primary mouse hepatocytes transfected with menin-speciﬁc or control shRNA. (G) mRNA levels of genes involved in fatty acid oxidation in primary hepatocytes
transfected with menin or control shRNA viruses, n = 8. (H) Restoration of hepatic menin expression promoted genes expression in livers from obese db/db mice, n = 6.
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agreement, overexpression of menin in db/db mice activated the
expression of PPARalpha target genes (Fig. 4H).
4. Discussion
Menin is the product of the MEN1 tumor suppressor gene,
which participates in many cellular processes, including transcrip-
tion regulation, apoptosis and DNA repair [17]. As a transcriptional
regulator, menin is able to co-activate estrogen receptor alpha
(ERalpha) and PPARgamma mediated transcription [18,19]. Activa-
tion of transcription by menin also involves histone modiﬁcations.
It is shown that menin acts as a key component of MLL1 (KMT2A)
or MLL2 (KMT2B) protein complexes which have histone methyl-
transferase (HMT) activity speciﬁc for lysine 4 of histone H3
(H3K4) [16].
Here our data provide novel insights into liver-speciﬁc func-
tions of menin with further implications for the pathogenesis of
obesity-related fatty liver. The results of our studies are consistent
with mouse models in which hyperlipidemic conditions are associ-
ated with the down-regulation of hepatic menin expression. An
increased exposure of the liver to fatty acids might at least in partexplain the menin inhibition under these conditions, although
other additional stress signals such as hyperinsulinemia might also
contribute to the regulation of menin gene expression. Further-
more, menin inhibition is sufﬁcient to promote liver triglycerides
accumulation, thereby establishing a key role for it in metabolic
disorders.
PPARalpha agonists, such as ﬁbrates, are commonly prescribed
as a hypolipidemic drugs for NAFLD treatment [20]. PPARalpha
lowers TG accumulation by enhancing fatty acid oxidation and
stimulating clearance of TG-rich lipoproteins. Mice lack of PPARal-
pha is reported to be prone to liver steatosis and hypertriglyceride-
mia [5]. Here, our data indicate that menin act as a co-activator to
regulate its transcriptional activity. We studied the interaction
between menin and PPARalpha and found that this interaction
was not dependent on the presence of ligand. This is in contrast
to the interactions of menin with ERalpha and RXR, which are
ligand dependent and represent classical NR coactivator
interactions.
Together, our studies demonstrate that menin plays a critical
regulatory checkpoint in the prevention of liver steatosis. Menin
is a direct coactivator for PPARalpha mediated transcription by
recruiting other co-regulators to PPARalpha target genes.
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